Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 and ≤ 65 years * Follicular lymphoma confirmed by a biopsy at the last relapse. * 2nd, 3rd or 4th complete or partial response according to Cheson's criteria 1 (Annexe 1) * Relapse after autologous-SCT except if the absence of autologous SCT is due to a failure of collecting peripheral stem cells or investigator decision to not proceed to the autologous graft because of serious criteria * Relapse after at least one line of treatment with rituximab * Karnofsky index \> 70% * HLA Matched related or unrelated donor (10/10 matching; HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1) * Signed informed consent Exclusion Criteria: * Stable or progressive disease according to Cheson's criteria1 (Annexe 1) * Absence of treatment with rituximab before the last relapse * Cardiac insufficiency (ejection fraction \< 50% by echocardiography) * Pulmonary disease characterized by DLCO \< 60% * Renal insufficiency (clearance of creatinin \< 60 ml/min) * Hepatic disease characterized by ASAT and/or ALAT and/or total bilirubin \> 2 times the upper normal value except in case of Gilbert's disease or hepatic lymphoma * HIV positive test * Bacterial, Viral or Fungal uncontrolled infections * Pregnant or breast feeding woman * Cancer in the last 5 years except in case of cutaneous baso-cellular cancer or epithelioma "in situ" of the uterine cervix